Loading...

Acer Therapeutics Inc.

ACERNASDAQ
Healthcare
Biotechnology
$0.66
$-0.14(-17.95%)

Acer Therapeutics Inc. (ACER) Stock Overview

Explore Acer Therapeutics Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.3/100

Key Financials

Market Cap0
P/E Ratio-0.37
EPS (TTM)$-1.93
ROE3.01%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.62

ACER Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Acer Therapeutics Inc. (ACER) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.62.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.37 and a market capitalization of 0. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;